{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:48:02Z","timestamp":1782503282841,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01010-0","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T15:59:09Z","timestamp":1619625549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Novel Therapies for ANCA-associated Vasculitis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-6772","authenticated-orcid":false,"given":"Sara","family":"Monti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Brandolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Milanesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blerina","family":"Xoxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Delvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJM197908023010503","volume":"301","author":"AS Fauci","year":"1979","unstructured":"Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235\u20138.","journal-title":"N Engl J Med"},{"key":"1010_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"1010_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"1010_CR5","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/rheumatology\/kez575","volume":"59","author":"A Lafarge","year":"2020","unstructured":"Lafarge A, Joseph A, Pagnoux C, Pu\u00e9chal X, Cohen P, Samson M, et al. Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. Rheumatol Oxf Engl. 2020;59:2250\u20137.","journal-title":"Rheumatol Oxf Engl"},{"key":"1010_CR6","first-page":"i37","volume":"32","author":"D Cornec","year":"2017","unstructured":"Cornec D, Cornec-Le Gall E, Specks U. Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2017;32:i37\u201347.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"1010_CR7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.semarthrit.2020.09.010","volume":"50","author":"S Monti","year":"2020","unstructured":"Monti S, Quinn KA, Christensen R, Jayne D, Langford C, Lanier GE, et al. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials. Semin Arthritis Rheum. 2020;50:1314\u201325.","journal-title":"Semin Arthritis Rheum"},{"key":"1010_CR8","doi-asserted-by":"crossref","unstructured":"Furuta S, Sugiyama T, Umibe T, Kaneko Y, Amano K, Kurasawa K, et al. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open [Internet]. 2017 [cited 2019 Oct 15];7. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5778278\/","DOI":"10.1136\/bmjopen-2017-018748"},{"key":"1010_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Walsh M, Merkel PA, Peh C-A, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622\u201331 PEXIVAS opens new horizons on the management of patients with AAV by supporting the use of reduced-dose glucocorticoids and challenging the role of PLEX.","DOI":"10.1056\/NEJMc2004843"},{"key":"1010_CR10","doi-asserted-by":"crossref","unstructured":"\u2022 Chanouzas D, McGregor JAG, Nightingale P, Salama AD, Szpirt WM, Basu N, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019;20:\u201358 This study demonstrated that glucocorticoids pulses are not associated with better disease outcomes, but with a greater infections risk.","DOI":"10.1186\/s12882-019-1226-0"},{"key":"1010_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/BOR.0b013e32834120c1","volume":"23","author":"A Casian","year":"2011","unstructured":"Casian A, Jayne D. Plasma exchange in the treatment of Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr Opin Rheumatol. 2011;23:12\u20137.","journal-title":"Curr Opin Rheumatol"},{"key":"1010_CR12","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol JASN. 2007;18:2180\u20138.","journal-title":"J Am Soc Nephrol JASN"},{"key":"1010_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2020.03.010","volume":"76","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Niles JL. The fate of plasma exchange and glucocorticoid dosing in ANCA-associated vasculitis after PEXIVAS. Am J Kidney Dis Off J Natl Kidney Found. 2020;76:595\u20137.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"1010_CR14","doi-asserted-by":"crossref","unstructured":"Morris A, Geetha D. PEXIVAS challenges current ANCA-associated vasculitis therapy. Nat Rev Nephrol. 2020;16:373\u20134.","DOI":"10.1038\/s41581-020-0269-6"},{"key":"1010_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.kint.2017.09.018","volume":"93","author":"J Dick","year":"2018","unstructured":"Dick J, Gan P-Y, Ford SL, Odobasic D, Alikhan MA, Loosen SH, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int. 2018;93:615\u201325.","journal-title":"Kidney Int"},{"key":"1010_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.molimm.2015.06.005","volume":"68","author":"CGM Kallenberg","year":"2015","unstructured":"Kallenberg CGM, Heeringa P. Complement system activation in ANCA vasculitis: a translational success story? Mol Immunol. 2015;68:53\u20136.","journal-title":"Mol Immunol"},{"key":"1010_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molimm.2019.06.018","volume":"112","author":"LF Quintana","year":"2019","unstructured":"Quintana LF, Kronbichler A, Blasco M, Zhao M-H, Jayne D. ANCA associated vasculitis: the journey to complement-targeted therapies. Mol Immunol. 2019;112:394\u20138.","journal-title":"Mol Immunol"},{"key":"1010_CR18","doi-asserted-by":"publisher","first-page":"e0195680","DOI":"10.1371\/journal.pone.0195680","volume":"13","author":"S Deshayes","year":"2018","unstructured":"Deshayes S, Aouba A, Khoy K, Mariotte D, Lobbedez T, Martin SN. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13:e0195680.","journal-title":"PLoS One"},{"key":"1010_CR19","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.2215\/CJN.00120115","volume":"10","author":"L Manenti","year":"2015","unstructured":"Manenti L, Vaglio A, Gnappi E, Maggiore U, Allegri L, Allinovi M, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol CJASN. 2015;10:2143\u201351.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"1010_CR20","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"\u2022\u2022 Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol JASN. 2017;28:2756\u201367 First study to report the efficacy of avacopan and introducing the concept of an alternative to glucocorticoids in the management of AAV.","journal-title":"J Am Soc Nephrol JASN"},{"key":"1010_CR21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2:662\u201371.","journal-title":"ACR Open Rheumatol"},{"key":"1010_CR22","doi-asserted-by":"publisher","first-page":"e16664","DOI":"10.2196\/16664","volume":"9","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Evaluation of the safety and efficacy of avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide\/azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc. 2020;9:e16664.","journal-title":"JMIR Res Protoc"},{"key":"1010_CR23","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1681\/ASN.2019111197","volume":"31","author":"MC Moura","year":"2020","unstructured":"Moura MC, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody\u2013associated vasculitis with severe kidney disease. J Am Soc Nephrol. 2020;31:2688\u2013704.","journal-title":"J Am Soc Nephrol"},{"key":"1010_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","volume":"3","author":"FB Cortazar","year":"2018","unstructured":"Cortazar FB, Muhsin SA, Pendergraft WF, Wallace ZS, Dunbar C, Laliberte K, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep. 2018;3:394\u2013402.","journal-title":"Kidney Int Rep"},{"key":"1010_CR25","first-page":"63","volume":"34","author":"SP McAdoo","year":"2019","unstructured":"McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:63\u201373.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"1010_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","volume":"14","author":"M McClure","year":"2018","unstructured":"McClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol. 2018;14:580\u201391.","journal-title":"Nat Rev Rheumatol"},{"key":"1010_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"\u2022 Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78:399\u2013405 Supports the role of mycophenolate as induction of remission strategy for AAV.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.11801018","volume":"14","author":"J Tuin","year":"2019","unstructured":"Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol CJASN. 2019;14:1021\u20138.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"1010_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s). Ann Rheum Dis. 2014;73:1376\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","volume":"45","author":"A Berti","year":"2015","unstructured":"Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, et al. Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015;45:48\u201354.","journal-title":"Semin Arthritis Rheum"},{"key":"1010_CR31","doi-asserted-by":"publisher","first-page":"e1203","DOI":"10.1002\/cti2.1203","volume":"9","author":"R Sakai","year":"2020","unstructured":"Sakai R, Ito M, Yoshimoto K, Chikuma S, Kurasawa T, Kondo T, et al. Tocilizumab monotherapy uncovered the role of the CCL22\/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis. Clin Transl Immunol. 2020;9:e1203.","journal-title":"Clin Transl Immunol"},{"key":"1010_CR32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3109\/14397595.2016.1160968","volume":"26","author":"R Sakai","year":"2016","unstructured":"Sakai R, Kondo T, Kikuchi J, Shibata A, Chino K, Okuyama A, et al. Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. Mod Rheumatol. 2016;26:900\u20137.","journal-title":"Mod Rheumatol"},{"key":"1010_CR33","unstructured":"JPRN-JMA-IIA00325. Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis. Httpwwwwhointtrialsearchtrial2aspx Trialidjprn-Jma-Iia00325 [Internet]. 2019 [cited 2019 Jun 8]; Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01901006\/full"},{"key":"1010_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/rheumatology\/kez311","volume":"59","author":"T Shimizu","year":"2020","unstructured":"Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: a meta-analysis. Rheumatol Oxf Engl. 2020;59:959\u201367.","journal-title":"Rheumatol"},{"key":"1010_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/MD.0000000000000020","volume":"93","author":"J Springer","year":"2014","unstructured":"Springer J, Nutter B, Langford CA, Hoffman GS, Villa-Forte A. Granulomatosis with polyangiitis (Wegener\u2019s): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82\u201390.","journal-title":"Medicine (Baltimore)"},{"key":"1010_CR36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"\u2022\u2022 Karras A, Pagnoux C, Haubitz M, Groot K, de Puechal X, Tervaert JWC, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1662\u20138 Supports the efficacy and safety of a more prolonged remission maintenance treatment with azathioprine.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR37","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med"},{"key":"1010_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"\u2022\u2022 Terrier B, Pagnoux C, Perrodeau \u00c9, Karras A, Khouatra C, Auma\u00eetre O, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77:1150\u20136 Supports the efficacy and safety of a more prolonged remission maintenance treatment with rituximab.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR39","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M, Bonnotte B, N\u00e9el A, Agard C, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173:179\u201387.","journal-title":"Ann Intern Med"},{"key":"1010_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2020-eular.2717","volume":"79","author":"R Smith","year":"2020","unstructured":"Smith R, Jayne D, Merkel PA, on behalf of RITAZAREM Investigators. OP0026 a randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease. Ann Rheum Dis. 2020;79:19\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","volume":"71","author":"D Jayne","year":"2019","unstructured":"Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol Hoboken NJ. 2019;71:952\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"1010_CR43","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","volume":"18","author":"S Gopaluni","year":"2017","unstructured":"\u2022\u2022 Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017;18:112 Supports the efficacy and safety of rituximab for the induction and maintenance of remission in AAV.","journal-title":"Trials"},{"key":"1010_CR45","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166\u201373.","journal-title":"Arthritis Care Res"},{"key":"1010_CR46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/bmj.281.6244.836","volume":"281","author":"AJ Pinching","year":"1980","unstructured":"Pinching AJ, Rees AJ, Pussell BA, Lockwood CM, Mitchison RS, Peters DK. Relapses in Wegener\u2019s granulomatosis: the role of infection. Br Med J. 1980;281:836\u20138.","journal-title":"Br Med J"},{"key":"1010_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","volume":"120","author":"CA Stegeman","year":"1994","unstructured":"Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12\u20137.","journal-title":"Ann Intern Med"},{"key":"1010_CR48","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/rheumatology\/kex001","volume":"56","author":"A Salmela","year":"2017","unstructured":"Salmela A, Rasmussen N, Tervaert JWC, Jayne DRW, Ekstrand A, European Vasculitis Study Group. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatol Oxf Engl. 2017;56:965\u201372.","journal-title":"Rheumatol"},{"key":"1010_CR49","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/art.1780310821","volume":"31","author":"RA DeRemee","year":"1988","unstructured":"DeRemee RA. The treatment of Wegener\u2019s granulomatosis with trimethoprim\/sulfamethoxazole: illusion or vision? Arthritis Rheum. 1988;31:1068\u201374.","journal-title":"Arthritis Rheum"},{"key":"1010_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1001\/archotol.1989.01860280113028","volume":"115","author":"K Fukuda","year":"1989","unstructured":"Fukuda K, Yuasa K, Uchizono A, Matsuyama H, Shimada K, Ohyama M. Three cases of Wegener\u2019s granulomatosis treated with an antimicrobial agent. Arch Otolaryngol Head Neck Surg. 1989;115:515\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1010_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/oxfordjournals.qjmed.a030133","volume":"89","author":"E Reinhold-Keller","year":"1996","unstructured":"Reinhold-Keller E, De Groot K, Rudert H, N\u00f6lle B, Heller M, Gross WL. Response to trimethoprim\/sulfamethoxazole in Wegener\u2019s granulomatosis depends on the phase of disease. QJM Mon J Assoc Physicians. 1996;89:15\u201323.","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"Suppl 4","key":"1010_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/2047-783X-14-S4-265","volume":"14","author":"K Zycinska","year":"2009","unstructured":"Zycinska K, Wardyn KA, Zielonka TM, Krupa R, Lukas W. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res. 2009;14(Suppl 4):265\u20137.","journal-title":"Eur J Med Res"},{"key":"1010_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16\u201320.","journal-title":"N Engl J Med"},{"key":"1010_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/rheumatology\/kez236","volume":"59","author":"BK Tan","year":"2020","unstructured":"Tan BK, Crabol Y, Tasse J, Laurent F, Nekkab N, Vinter C, et al. No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. Rheumatol Oxf Engl. 2020;59:77\u201383.","journal-title":"Rheumatol Oxf Engl"},{"key":"1010_CR55","first-page":"1","volume":"3","author":"A Berti","year":"2017","unstructured":"Berti A, Specks U, Keogh K, Cornec D. Current and future treatment options for eosinophilic granulomatosis with polyangiitis. Curr Treat Options Rheumatol. 2017;3:1\u201314.","journal-title":"Curr Treat Options Rheumatol"},{"key":"1010_CR56","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"\u2022\u2022 Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921\u201332 First trial to demonstrate the efficacy of mepolizumab in EGPA leading to the first targeted-treatment for EGPA.","journal-title":"N Engl J Med"},{"key":"1010_CR57","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","volume":"143","author":"J Steinfeld","year":"2019","unstructured":"Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2019;143:2170\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1010_CR58","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrrheum.2017.117","volume":"13","author":"L Guillevin","year":"2017","unstructured":"Guillevin L. Mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol Nature Publishing Group. 2017;13:518\u20139.","journal-title":"Nat Rev Rheumatol"},{"key":"1010_CR59","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14712598.2019.1623875","volume":"19","author":"D Ennis","year":"2019","unstructured":"Ennis D, Lee JK, Pagnoux C. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opin Biol Ther. 2019;19:617\u201330.","journal-title":"Expert Opin Biol Ther"},{"key":"1010_CR60","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/annrheumdis-2020-eular.5544","volume":"79","author":"A Bettiol","year":"2020","unstructured":"Bettiol A, Urban ML, Alberici F, Agostini C, Baldini C, Bozzolo E, et al. Op0148 Mepolizumab for eosinophilic granulomatosis with polyangiitis (egpa): a retrospective real-world European study on 142 patients. Ann Rheum Dis BMJ Publishing Group Ltd. 2020;79:94\u20135.","journal-title":"Ann Rheum Dis BMJ"},{"key":"1010_CR61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","volume":"53","author":"A Detoraki","year":"2016","unstructured":"Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma Off J Assoc Care Asthma. 2016;53:201\u20136.","journal-title":"J Asthma Off J Assoc Care Asthma"},{"key":"1010_CR62","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","volume":"68","author":"M Jachiet","year":"2016","unstructured":"Jachiet M, Samson M, Cottin V, Kahn J-E, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheum Hoboken NJ. 2016;68:2274\u201382.","journal-title":"Arthritis Rheum"},{"key":"1010_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40413-018-0217-0","volume":"11","author":"Z Celebi Sozener","year":"2018","unstructured":"Celebi Sozener Z, Gorgulu B, Mungan D, Sin BA, Misirligil Z, Aydin O, et al. Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases. World Allergy Organ J. 2018;11:39.","journal-title":"World Allergy Organ J"},{"key":"1010_CR64","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.anai.2016.12.003","volume":"118","author":"S Nazir","year":"2017","unstructured":"Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2017;118:372\u2013374.e1.","journal-title":"Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol"},{"issue":"Suppl 124","key":"1010_CR65","first-page":"214","volume":"38","author":"F Basta","year":"2020","unstructured":"Basta F, Mazzuca C, Nucera E, Schiavino D, Afeltra A, Antonelli IR. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review. Clin Exp Rheumatol. 2020;38(Suppl 124):214\u201320.","journal-title":"Clin Exp Rheumatol"},{"key":"1010_CR66","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry M-J, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75:396\u2013401.","journal-title":"Ann Rheum Dis"},{"key":"1010_CR67","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5:e000905.","journal-title":"RMD Open"},{"key":"1010_CR68","first-page":"1583","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. BMJ Publishing Group Ltd. 2016;75:1583\u201394.","journal-title":"BMJ"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01010-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01010-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T05:16:58Z","timestamp":1675228618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01010-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01010-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"38"}}